These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 11138599

  • 1. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [Abstract] [Full Text] [Related]

  • 3. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
    Fung HB, Kirschenbaum HL.
    Clin Ther; 1999 Jul; 21(7):1131-57. PubMed ID: 10463513
    [Abstract] [Full Text] [Related]

  • 4. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
    Peretz A.
    Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
    [Abstract] [Full Text] [Related]

  • 5. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A, Krahn M, Naglie G.
    Arthritis Rheum; 2003 Jun 15; 49(3):283-92. PubMed ID: 12794781
    [Abstract] [Full Text] [Related]

  • 6. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ, Wentworth C, Burke TA, Makuch RW.
    Pharmacoepidemiol Drug Saf; 2004 May 15; 13(5):277-87. PubMed ID: 15133778
    [Abstract] [Full Text] [Related]

  • 7. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 15; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [Abstract] [Full Text] [Related]

  • 8. Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases.
    Gibofsky A.
    J Hypertens Suppl; 2002 Sep 15; 20(6):S25-30. PubMed ID: 12683424
    [Abstract] [Full Text] [Related]

  • 9. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC.
    Semin Arthritis Rheum; 2002 Dec 15; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [Abstract] [Full Text] [Related]

  • 10. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 11. [A critical evaluation of side effect data on COX-2 inhibitors].
    Pomp E.
    Tidsskr Nor Laegeforen; 2002 Feb 20; 122(5):476-80. PubMed ID: 11961974
    [Abstract] [Full Text] [Related]

  • 12. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS.
    Scand J Rheumatol Suppl; 1999 Feb 20; 109():31-7. PubMed ID: 10422544
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Selective cyclooxygenase-2 inhibitors and the digestive tract].
    Chaabouni H, Amouri A, Cheikh I, Kchaou M, Ouerghi H, Ben Mami N, Ben Ammar A.
    Tunis Med; 2002 Aug 20; 80(8):427-33. PubMed ID: 12703120
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
    Linder JD, Mönkemüller KE, Davis JV, Wilcox CM.
    South Med J; 2000 Sep 20; 93(9):930-2. PubMed ID: 11005360
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
    Goldstein JL, Correa P, Zhao WW, Burr AM, Hubbard RC, Verburg KM, Geis GS.
    Am J Gastroenterol; 2001 Apr 20; 96(4):1019-27. PubMed ID: 11316141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.